Despite the regulatory setback, BioArctic's partner Eisai has stated that the safety profile of lecanemab reported in clinical practice in the United States, Japan, and other countries is consistent ...

AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...

The European Commission (EC) has presented data regarding several criminal proceedings linked to the enforcement of EU law, with Bulgaria involved in seven of these cases. In the realm of crime ...

The European Commission said on Friday that it has launched infringement procedures against Bulgaria for failing to fully ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

Merck (MRK) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, recommended ...

Unife has warned that EU member states are at risk of losing funding for vital rail schemes promised in the EU's Recovery and ...

Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Five years on, Brexit is still the gift that keeps on taking - THE INDEPENDENT VIEW: Editorial: In 2025, regret is the ...

The European Commission has announced the Africa-EU Space Partnership Programme, an initiative, backed by a €100 million (about US$103.8 million) investment, that, the EU says, forms a critical part ...

The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly ...